ReviewExpert review of anti-infective therapy2010
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.
Review in Expert review of anti-infective therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.Genome medicine · 2021Trial
- Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.The Journal of antimicrobial chemotherapy · 2016Trial
- Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.Antimicrobial agents and chemotherapy · 2015Trial
- Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Trial
- The effect of novel antimicrobial agents on the normal functioning of human intestinal microbiota: a systematic review.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Review
- Iron Effects onAntibiotics (Basel, Switzerland) · 2022Article
- Comparison of polysaccharide glycoconjugates as candidate vaccines to combat Clostridiodes (Clostridium) difficile.Glycoconjugate journal · 2021Article
- Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure inOpen forum infectious diseases · 2021Article
- Strong Antimicrobial Effects of Xanthohumol and Beta-Acids from Hops againstAntibiotics (Basel, Switzerland) · 2021Article
- PathoFact: a pipeline for the prediction of virulence factors and antimicrobial resistance genes in metagenomic data.Microbiome · 2021Article
- Physician Perceptions on the Use of Antibiotics and Probiotics in Adults: An International Survey in the Asia-Pacific Area.Frontiers in cellular and infection microbiology · 2021Article
- Benzyl and benzoyl benzoic acid inhibitors of bacterial RNA polymerase-sigma factor interaction.European journal of medicinal chemistry · 2020Article
- Refining theMicroorganisms · 2020Article
- Integrated genomic epidemiology and phenotypic profiling of Clostridium difficile across intra-hospital and community populations in Colombia.Scientific reports · 2019Article
- Efficacy of an Optimised Bacteriophage Cocktail to Clear Clostridium difficile in a Batch Fermentation Model.Antibiotics (Basel, Switzerland) · 2018Article
- Toward the total synthesis of luminamicin; an anaerobic antibiotic: construction of highly functionalized cis-decalin containing a bridged ether moiety.The Journal of antibiotics · 2018Article
- Novel Antimicrobials for the Treatment ofFrontiers in medicine · 2018Review
- A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment.Journal of visualized experiments : JoVE · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Clostridium difficile infection (CDI) is the most common cause of identifiable diarrhea in hospitalized patients. The incidence and severity of CDIs are increasing. The increased incidence and severity of the disease has sparked interest in the optimal treatment of CDI as well as the use of new therapies and drug discovery. Current treatment strategies are inadequate with decreased response rates to metronidazole, and high recurrence rates with the use of metronidazole and oral vancomycin. Although incidence rates continue to be low, in vitro resistance to antibiotics used for the treatment of CDI has been noted. Recently, important data has emerged on new anti-C. difficile antibiotics such as rifaximin, rifalazil, fidaxomicin, nitazoxanide, tigecycline and ramoplanin. The purpose of this review is to provide an update on the in vitro susceptibility and new antibiotic treatment options for CDI. This review will focus primarily on scientific studies published in the last 36 months in order to provide an up-to-date review on the topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.